phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - agentes antineoplásicos - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - mieloma múltiple - agentes antineoplásicos - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
melfalan zentiva 50 mg polvo y disolvente para solucion inyectable y para perfusion efg
zentiva k.s. - melfalan hidrocloruro - polvo y disolvente para soluciÓn inyectable y para perfusiÓn - 50 mg - melfalan hidrocloruro 50 mg - melfalán
bicavan liofilizado para solucion inyectable 2,5 mg (bortezomib)
synthon chile ltda. - bortezomib - sin formulas
melfoma 2 melfalan 2 mg comprimido recubierto
pharmaris peru s.a.c. - melfalan; - comprimido recubierto - por comprimido; melfalan 2.000000 mg; - melfalan
egymelan 50 mg polvo para concentrado para solucion para perfusion
oqcorp sociedad anonima cerrada - oqcorp s.a.c. - droguerÍa - melfalan; - polvo para concentrado para solucion para perfusion - por vial 1.00 vial - - melfalan
melfoma 50 50 mg polvo liofilizado para solucion inyectable
pharmaris peru s.a.c. - melfalan; - polvo liofilizado para solucion inyectable - por vial1 vial; melfalan 50.000000 mg; - melfalan
melfalan comprimidos 2 mg
varifarma chile s.p.a. - melfalan - sin formulas
melfalan 2 mg comprimido
varifarma peru s.a.c. - droguerÍa - comprimido - por comprimido - - melfalan
lenalidomide krka d.d. novo mesto (previously lenalidomide krka)
krka, d.d., novo mesto - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - inmunosupresores - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) está indicado para el tratamiento de pacientes adultos no tratados previamente con mieloma múltiple que no son elegibles para el trasplante. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) está indicado para el tratamiento de pacientes adultos no tratados previamente con mieloma múltiple que no son elegibles para el trasplante. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).